Conditions: Liver Cancer
Keywords: liver cancer, second line
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 41
Healthy volunteers: no

Brief summary:
This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.

Detailed description:
This study will determine the response rate and toxicities of lenalidomide as second line treatment for patients with liver cancer who have progressed after sorafenib.

Arms:
arm 1: None

Interventions: intervention 1: lenalidomide
Intervention descriptions: intervention 1: 25 mg po qd x 21 days then 1 week off equals one cycle

Protocol document: